EichorEICHOR
Condition: Egfr Exon 20 Mutation Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Egfr Exon 20 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR
Phase 2 · 80 location(s) · Taiho Oncology, Inc. · NCT05967689First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H
Phase 1/Phase 2 · 24 location(s) · Pierre Fabre Medicament · NCT06043817Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Phase 2 · 3 location(s) · Tang-Du Hospital · NCT06864624Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Phase 1/Phase 2 · 42 location(s) · ORIC Pharmaceuticals · NCT05315700A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Phase N/A · 3 location(s) · National Cancer Centre, Singapore · NCT06418412ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Phase 1 · 4 location(s) · ORIC Pharmaceuticals · NCT06816992A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Can
Phase 3 · 49 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07182682To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Posi
Phase 2 · 1 location(s) · Juan LI, MD · NCT06192849Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · BeBetter Med Inc · NCT06706713Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
NA · 18 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06247826Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Ca
Phase N/A · 16 location(s) · GFPC Investigation · NCT07563205Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 344 location(s) · National Cancer Institute (NCI) · NCT03191149
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.